Oncimmune Holdings PLC Consortium of Liver Cancer Industry Leaders
January 23 2020 - 6:30AM
RNS Non-Regulatory
TIDMONC
Oncimmune Holdings PLC
23 January 2020
23 January 2020
Oncimmune Holdings plc
("Oncimmune" or the "Company")
Oncimmune included in Consortium of Liver Cancer Industry
Leaders to Research Early Detection
Oncimmune Holdings plc (AIM: ONC.L), a leading global
immunodiagnostics group, today announces that it has been included
in a consortium of industry leaders, brought together by the Oxford
Centre for Early Cancer Detection (OxCODE), to aid in the research
of earlier detection of hepatocellular carcinoma.
The programme aims to understand more about changes in the liver
as hepatocellular carcinoma develops in order to use this
information to inform new and more sensitive diagnostic tests that
could detect liver cancer earlier.
The Chief Investigator of the programme, Professor Ellie Barnes
has been awarded a Cancer Research UK (CRUK) Early Detection
Programme Award that provides funding of GBP2.5 million over the
next five years to support the programme.
Alongside a multidisciplinary team involving multiple Oxford
researchers, the consortium also includes researchers from
Nottingham University, Newcastle University, Glasgow Caledonian
University, the University of Bristol, the London School of Hygiene
and Tropical Medicine and Aarhus University (Denmark), and industry
partners including Oncimmune, Roche Diagnostics, Perspectum
Diagnostics, and IPDx; and charity partners the British Liver Trust
and the Hepatitis C Trust.
Dr Adam M Hill, Chief Executive Officer of Oncimmune,
commented:
"Our participation in this consortium further demonstrates our
success of being recognised as a world leading immunodiagnostic
group focused on earlier cancer detection. Through this programme
and our expertise, better techniques will be developed and executed
in order to diagnose liver cancer at an earlier stage giving
patients a greater chance of survival."
-Ends-
For further information:
Oncimmune Holdings plc
Adam Hill, Chief Executive Officer
Matthew Hall, Chief Financial Officer
contact@oncimmune.com
Zeus Capital Limited (Nominated Adviser and Joint Broker)
Andrew Jones, Daniel Harris, Victoria Ayton
+44 (0)20 3829 5000
finnCap (Joint Broker)
Geoff Nash, Matthew Radley, Tim Redfern
+44 (0)20 7220 0500
Bryan, Garnier & Co Limited (Joint Broker)
Phil Walker, Dominic Wilson
+44 (0)20 7332 2500
Media enquiries:
FTI Consulting
Ben Atwell, Michael Trace, Alex Davis
oncimmune@fticonsulting.com
+44 (0)20 3727 1000
About Oncimmune
Beating cancer, one test at a time
Oncimmune is a leader in the development, manufacture and
commercialisation of cancer specific immunodiagnostics for the
screening, detection and care of cancer. Oncimmune also develops
precision medicine and patient stratification tools for leading
pharmaceutical multinationals in both autoimmune disease and
immuno-oncology. Oncimmune is working to change how cancer is
diagnosed and treated. Its patented technology detects evidence of
the body's natural response to cancer, enabling detection four
years or more before standard clinical diagnosis. Oncimmune's tests
facilitate clinical decision-making and are complementary to
diagnostic technologies, making them valuable additions to
established and new care pathways. Oncimmune partners with leading
developers and distributors to make our technology available
globally.
Oncimmune was founded in 2002 and launched its platform
technology in 2009, followed by its first commercial tests,
EarlyCDT Lung and EarlyCDT(R) Liver. To date, over 155,000 tests
have been performed for patients worldwide. EarlyCDT Lung was also
used in what is believed to be the largest randomised controlled
study for the early detection of lung cancer using biomarkers, the
successful National Health Service (NHS) ECLS study of 12,210
high-risk smokers in Scotland which demonstrated EarlyCDT Lung
reduced the incidence of patients with late-stage lung cancer or
unclassified presentation at diagnosis, compared to standard
clinical practice.
Oncimmune, headquartered at its laboratory facility in
Nottingham, UK, has a discovery research centre in Dortmund,
Germany and a CLIA lab in Kansas, US as well as an office in
London, UK and a partner representative office in Shanghai, China.
Oncimmune joined the Alternative Investment Market (AIM) of the
London Stock Exchange in May 2016 under the ticker ONC.L.
What is EarlyCDT Lung?
A blood test using a panel of seven immunogenic proteins for the
testing of tumour-related antibodies specific to lung cancer.
For more information, visit www.oncimmune.com.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
NRASEMFEDESSEEF
(END) Dow Jones Newswires
January 23, 2020 07:30 ET (12:30 GMT)
Oncimmune (LSE:ONC)
Historical Stock Chart
From Apr 2024 to May 2024
Oncimmune (LSE:ONC)
Historical Stock Chart
From May 2023 to May 2024